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Abstract Blood flukes or schistosomes are the
causative agents of human schistosomiasis, one of
the major neglected tropical diseases. Draft genome
sequences have been reported for schistosomes, but
functional genomics tools are needed to investigate the
role and essentiality of the newly reported genes.
Vector based RNA interference can contribute to
functional genomics analysis for schistosomes. Using
mRNA encoding reporter firefly luciferase as a model
target, we compared the performance of a schistosome
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and a human promoter from the U6 gene in driving
shRNA in human fibrosarcoma cells and in cultured
schistosomes. Further, both a retroviral [Murine
leukemia virus (MLV)] and plasmid (piggyBac,
pXL-Bac II) vector were utilized. The schistosome
U6 gene promoter was 270 bp in length, the human U6
gene promoter was 264 bp; they shared 41% identity.
Following transduction of both HT1080 fibrosarcoma
cells and schistosomules of Schistosoma mansoni with
pseudotyped MLV virions, stronger knockdown of
luciferase activity was seen with the virions encoding
the human U6 promoter driven shRNA than the
schistosome U6 promoter. A similar trend was seen
after transfection of HT1080 cells and schistosomules
with the pXL-Bac-II constructs—stronger knockdown
of luciferase activity was seen with constructs encoding the human compared to schistosome U6 promoter.
The findings indicate that a human U6 gene promoter
drives stronger shRNA activity than its schistosome
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orthologue, not only in a human cancer cell line but
also in larval schistosomes. This RNA polymerase III
promoter represents a potentially valuable component
for vector based RNA interference studies in schistosomes and related platyhelminth parasites.
Keywords Schistosome  Schistosoma mansoni 
Short hairpin RNA  U6 gene  Promoter  Firefly
luciferase  RNA interference  Murine leukemia
virus  piggyBac transposon

Introduction
Vector-based RNAi approaches that lead to chromosomal integration of transgenes encoding cassettes
expressing small interfering RNAs (siRNAs) can
circumvent deficiencies with cytoplasmic RNAi
approaches by providing long-term, continuous and/
or conditional gene silencing (ter Brake et al. 2006;
Moore et al. 2010; Sliva and Schnierle 2010). By
contrast, delivery of dsRNAs/siRNAs from the exterior of the cell to the cytoplasm frequently delivers
only transitory gene silencing, may be inaccessible to
some developmental stages and/or tissues, can be
expensive and, in addition, cytoplasmic dsRNAs may
induce apoptosis and interferon signaling responses in
some situations (Haasnoot et al. 2007; Sliva and
Schnierle 2010; Handa et al. 2011).
The schistosomes are considered the most important
of the human helminth parasites in terms of the
morbidity and mortality which they cause (Hotez et al.
2008; Han et al. 2009; Rollinson 2009; Gurarie et al.
2011). In addition, Schistosoma haematobium is a
cause of squamous cell carcinoma of the bladder and is
classified as a Group 1 carcinogen by the International
Agency for Research on Cancer (Bouvard et al. 2009).
Following the recent reports of the draft genome
sequences of two of the major human schistosome
species (Berriman et al. 2009; Schistosoma japonicum
Genome Sequence and Functional Analysis Consortium 2009), efforts have increased towards harnessing
the functional genomics approaches widely used in
model species and human gene therapy for investigation of the importance and essentiality of these new
schistosome genes (Stefanic et al. 2010; Collins et al.
2011). Information obtained with these advances can
be expected to guide development of new interventions
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for these major neglected tropical disease pathogens
(Brindley et al. 2009; Han et al. 2009).
In relation to this interest in expanding functional
genomics for schistosomes, it has been demonstrated
that both pseudotyped murine leukemia virus (MLV)
and the transposon piggyBac can transduce developmental stages of schistosomes, leading to chromosomal integration of retroviral transgenes and
transgene reporter activity (Morales et al. 2007; Kines
et al. 2008; Yang et al. 2010; Rinaldi et al. 2011).
Moreover, vector-based RNAi approaches have been
reported in schistosomes (e.g. Zhao et al. 2008). The
goal of the present investigation was to compare and
contrast the performance of two U6 gene promoters,
one from S. mansoni, the other from the human
genome, in driving short hairpin RNAs in cultured
schistosomes. There may be advantages to deploying a
RNA polymerase (Pol III) promoter: the U6 promoter
is known to competently and continuously transcribe
small RNAs, is highly active in all or most cells and
tissues where this has been examined (information on
this aspect is not available for schistosomes, so it is not
known whether Pol III is likewise widely active in
cells of this flatworm), and its diminutive size fits
within the limits on cargo size of the expression
cassette (Paddison et al. 2002; Scherr and Eder 2007).
Defining active promoter elements for vector based
RNAi in schistosomes can be expected to be worthwhile since studies of the human schistosomes are
more problematic than established approaches with
cultured mammalian cells or with more well studied
model species such as Caenorhabditis elegans and
Drosophila melanogaster. The present findings
revealed the superior performance of a human U6
promoter when compared to an endogenous U6
promoter from S. mansoni in driving active shRNAs
in cultured schistosomes.

Materials and methods
HT1080 fibrosarcoma cells expressing firefly
luciferase
We employed a genetically modified HT1080 human
fibrosarcoma cell line, that constitutively expresses
luciferase, in these studies of short hairpin RNA
(Ayuk et al. 2011). In brief to generate a HT1080 cell
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line stably expressing luciferase, HT1080 cells
(ATCC, Manassas, VA) were transduced with lentivirus virions (ViraPower Promoterless Lentiviral
Gateway Expression System, Invitrogen) that includes
a gene conferring resistance to blasticidin, and the
firefly luciferase gene driven by the S. mansoni spliced
leader RNA gene promoter (see Kines et al. 2006) in
the presence of polybrene (Sigma). Blasticidin-resistant cells expressing luciferase were selected by
culturing in the presence of blasticidin for 14 days.
Stable cells were isolated, cryopreserved and/or
expanded for use as target, luciferase expressing
HT1080 cells for the vector based RNAi (below).
Schistosoma mansoni
Biomphalaria glabrata snails infected with the NMRI
(Puerto Rican) strain of S. mansoni were supplied by
Dr. Fred Lewis, Biomedical Research Institute, Rockville, MD, USA. Cercariae released from infected
B. glabrata snails were mechanically transformed into
schistosomules. In brief, cercariae were concentrated
by centrifugation (425 g/10 min) and washed once
with schistosomule wash medium (Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
200 units/ml of penicillin, 200 lg/ml of streptomycin,
500 ng/ml of amphotericin B and 10 mM HEPES).
Cercarial tails were sheared from the larvae by 20
passes through 22 gauge emulsifying needles after
which schistosomule bodies were isolated from tails
by Percoll gradient centrifugation (Lazdins et al.
1982). Schistosomula were washed three times in
schistosomule wash medium and cultured in Basch’s
medium (Basch 1981) at 37°C under 5% CO2 in air for
up to 14 days. Some cultures were supplemented with
washed human erythrocytes, at a density of 1 ll of
packed red cells per ml of medium (Mann et al. 2010).
Construction of shRNA expression cassettes
targeting firefly luciferase
The sequence of the human U6 small nuclear RNA
gene (GenBank X07425) was used to design primers
HsU6F and HsU6R (Table S1) and the primers
employed to amplify upstream and part of the
50 -terminus of the U6 gene from genomic DNA from
human white blood cells using a kit (ENZA, Omega
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Bio-tek, Doraville, GA). The amplicon was ligated
into pCR4 TOPO (Invitrogen), the insert sequenced,
the nucleotide sequence aligned with other human and
schistosome U6 promoters, and this human U6
promoter sequence included in the shRNA expression
cassette in the MLV pLNHXDD70 (generated by the
removal of Drosophila heat shock 70 gene promoter
from pLNHX using Xho I) (Suttiprapa, unpublished)
and piggyBac (pXL-BacII) constructs assembled here
(Fig. 1). The S. mansoni U6 promoter has been
described (Ayuk et al. 2011).
A two-step PCR approach was performed to
construct the shRNA expression cassettes targeting
firefly luciferase (Gou et al. 2003; Linford et al. 2009;
Ayuk et al. 2011) that included either a human or a
schistosome U6 promoter. The approach involved two
rounds of PCR using one universal primer, specific for
the promoter (human or schistosome) and two unique
target sequences, the first oligonucleotide to add the
sense strand of the shRNA, the second to add the loop
region, anti-sense strand and terminal thymidines. For
the hairpin sense strand, we included 21 residues,
nucleotides 851-871, 50 -GTGCGCTGCTGGTGCCA
ACCC-30 , of the firefly luciferase (cDNA) gene in
pGL3 (Promega) because this site and target sequence
length have been demonstrated in shRNA studies to
lead to complete or near complete knockdown of
luciferase activity in mammalian and insect cell lines
(Gou et al. 2003; Wakiyama et al. 2005). For a control
shRNA, we constructed cassettes where the 21 target
residues 851-871 of the luciferase gene were scrambled, as follows, 50 -ACCTACTGGGCAGGGAGCC
GC-30 , using the same forward primer (above) and the
reverse primers (Table S1). The final products were
sized by agarose gel electrophoresis, eluted from gel,
cleaved with Xho I for pLNHX and BamH I and Xho I
for pXL-Bac II (Li et al. 2005), and ligated into
linearized retroviral or transposon vector plasmids.
Figure 1 provides an illustration of the constructs,
termed pLNHX_SmU6_shLuc (GenBank accession JN255692), pLNHX_HsU6_shLuc (JN255690),
pLNHX_HsU6_ScramLuc (JN255691), pXL-BacII_SmU6-shLuc (HQ677838), pXL-BacII_SmU6shScramLuc (HQ677839), pXL-BacII_HsU6-shLuc
(JF298906), and pXL-BacII_HsU6-shScramLuc
(JF298907). Sequences of oligonucleotide primers
used in assembly of these shRNA expression cassettes
are provided in Table S1.
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Fig. 1 Schematic illustration of the retroviral pLNHX (murine
leukemia virus, MLV) and pXL-Bac II (transposon piggyBac)
based plasmids (left) and shRNA expression cassettes (right)
modified here by insertion of shRNA expression cassettes. The
shRNA expression cassettes target firefly luciferase or a

‘scrambled’ control sequence. MCS Multiple cloning site, ITR
inverted terminal repeat (regions of the transposon), LTR long
terminal repeat (of the retrovirus), cHS4 chicken DNase-I
hypersensitive site 4 (a prototypic chromatin insulator)

Production of pseudotyped retroviral virions

Messenger RNA encoding firefly luciferase

Plasmid constructs, prepared with a maxiprep kit (5
Prime, Gaithersburg, MD), were employed to produce
the virions as described (Kines et al. 2010; Rinaldi
et al. 2011). In brief, GP2-293 cells were co-transfected with the MLV encoding plasmid (Fig. 1) along
with pVSVG, which encodes vesicular stomatitis virus
glycoprotein (the pseudotyping envelope) using liposomes (Lipofectamine 2000, Invitrogen). Culture
supernatants were collected 48 h later, filtered through
0.45 lm pore size membranes, the filtrate incubated
with DNAse I (New England Biolabs, Ipswich, MA) to
remove contaminating plasmids, and virions in culture
supernatants recovered by centrifugation (Sorvall
SS34 rotor, 50,000g, 90 min, 4°C). Pelleted virions
were resuspended in schistosomule wash medium
(above), virion titers estimated using quantitative PCR
(Mann et al. 2011), and aliquots of virions stored at
-80°C until needed. pLNHXDD70 was employed to
produce control virions without shRNA encoding
cassettes.

For preparation of firefly luciferase mRNAs (mLuc),
in vitro transcriptions of capped RNAs from template
PCR products from the luciferase gene in pGL3Basic (Promega) were accomplished using the mMessage mMachine T7 Ultra kit (Ambion) (Correnti
and Pearce 2004). mLuc was precipitated with one
volume of 5 M ammonium acetate and 2.5 volumes of
95% ethanol after which the precipitate was dissolved
in water and concentration and purity determined
using a ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE).
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Transduction of HT1080 cells
Luciferase expressing HT1080 cells were plated at a
density of 2 to 5 9 105 in 6-well (35 mm) plates to
achieve 30–50% confluence the following day. For
transduction with retroviral virions, pLNHX_
HsU6_shLuc or pLNHX_HsU6_Scram control virions (6.5 9 108 virions) were added to the cells which
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were then cultured for 18 h in 2 ml of DMEM
supplemented with 10% FBS, 100 units/ml of penicillin, 100 lg/ml of streptomycin and 8 lg/ml polybrene. Culture media were changed the following day.
The transduced cells were harvested at 96 h after
addition of virions. For some experiments, transduced
HT1080 cells were subjected to selection on G418 at
500 lg/ml for 10 days, since the retroviral encodes the
neomycin resistance gene (Fig. 1), with changes of
culture media every second day. After harvesting,
cells were counted and lysed in CCLR buffer
(Promega) in order to determine levels of luciferase
activity (below).
In like fashion, HT1080 cells at *90% confluence
were transfected with 4 lg of plasmid pXL-BacII_
SmU6-shLuc, pXL-BacII_SmU6-shScramLuc, pXLBacII_HsU6-shLuc or pXL-BacII_HsU6-shScramLuc
using Lipofectamine 2000. A control group of cells not
transfected with plasmids but exposed to the liposomes
was included (mock). The following day, cells were
washed with 19 PBS, and then cultured for 96 h in
DMEM supplemented with 10% FBS, 100 units/ml of
penicillin, 100 lg/ml of streptomycin. Cells were
counted and lysed, as above.
Transduction of schistosomules
For transduction of schistosomes, virions—at titers
ranging from 2.6 9 109 to 1.5 9 1010 per treatment
well—were added to cultures of 7 day old schistosomules, 103–104 schistosomules per well (24-well
plates; Corning) in one ml schistosomule media
containing 8 lg/ml polybrene. Media were changed
at 18 h after addition of virions, after which schistosomules were maintained in culture for 3 days. At this
point these schistosomules were transfected with
mRNA encoding firefly luciferase. Three hours after
electroporation the parasites were harvested for luciferase activity assays. In some experiments, the
schistosomules were exposed to the virus by centrifugation (800g, 60 min, 21°C) in the presence of
polybrene.
Schistosomules were transfected with pXL-Bac II
constructs by square wave electroporation; the worms
were transferred to cuvettes (4 mm gap, BTX, San
Diego, CA, USA) containing media supplemented
with 20 lg of plasmid (pXL-BacII_ SmU6-shLuc or
pXL-BacII_SmU6-shScramLuc or pXL-BacII_ HsU6shLuc or pXL-BacII_HsU6-shScramLuc) and then
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subjected to a square wave pulse of 125 V of 20 ms
duration, using a BTX ElectroSquarePoratorTM
ECM830, as described (Kines et al. 2010). Transfected
worms were transferred to pre-warmed Basch’s
medium and maintained in culture for 48 h. mRNA
encoding firefly luciferase was introduced into the
cultured worms by electroporation (using the same
conditions as for the plasmids). After electroporation,
the schistosomules were maintained in culture for 3 h
and then washed free of culture media, and wet pellets
of worms snap frozen and stored at -80°C. [It is
pertinent to note that exposing worms twice to
electroporation may be deleterious, and reflected in
inconsistent outcomes in the replicates (Ayuk et al.
2011)].
Luciferase activity assay
HT1080 cells and schistosomules were harvested,
lysed, clarified supernatant (after centrifugation of
lysates, 10,000g, 10 min 4°C), analyzed for luciferase
activity. Aliquots of 100 ll of lysate were injected
into100 ll luciferin (Promega) at 25°C, mixed, and
the relative light units (RLUs) determined in a tube
luminometer (Sirius, Berthold, Pforzheim, Germany)
10 s later (Correnti and Pearce 2004). Replicate
samples were measured, with results presented as
the average of the readings of relative light units
(RLU) per second per lg of soluble HT1080 or
schistosome protein. Recombinant firefly luciferase
(Promega) was included as a positive control in order
to verify that the luciferin substrate and luminometer
were functioning in a normal, expected fashion.
Protein concentration of soluble fractions of transduced HT1080 cell and schistosome extracts were
determined using the bicinchoninic acid assay (BCA
kit, Pierce, Rockford, IL).

Results
U6 promoters diverge between schistosomes
and humans
Whereas it was clear from a recent study that a U6
promoter from S. mansoni drove shRNA expression
(Ayuk et al. 2011), here we compared the performance of a human U6 promoter with a schistosome
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JN255693 was included as the promoter in shRNA
expression cassettes constructed here (Fig. 1).

orthologue since the human U6 promoter is used
widely in shRNA studies (Makinen et al. 2006; Roelz
et al. 2010), including its inclusion as the promoter in
the commercial vector pENTR/U6 from Invitrogen.
Several U6 genes from the human genome are active
although it appears that the promoter termed U6-1 is
the widely utilized variant (Kunkel and Pederson
1988; Domitrovich and Kunkel 2003) (GenBank
X07425). We aligned the X07425 sequence, the
human U6 promoter from pENTR/U6 (here termed
Invitrogen_U6), and GenBank JN255693, a variant of
the human U6 promoter we cloned and sequenced
from the blood donated by a co-author of this report,
and a S. mansoni U6 gene promoter (HQ540317)
(alignment not shown but available from corresponding author). The schistosome U6 gene promoter was
270 bp in length, the human U6 gene promoter was
264 bp, and they shared 41% identity. By contrast, the
three human orthologues aligned were nearly identical; X07425 differed from JN255693 and Invitrogen_U6 by the inclusion of an additional residue, a
thymidine (T) at position-98. This T occurred outside
conserved Pol III binding domains, SPH, OCT, PSE
and TATA, which were identical in the three human
sequences. However, clear differences were apparent
in all four domains between the schistosome
(HQ540317) and human U6 promoters (Ayuk et al.
2011). The human U6 gene promoter in GenBank
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HT1080 fibrosarcoma cells

Human U6 promoter drives shRNA activity
in schistosomes
At the outset, we examined the human U6 promoter in
the context of transduction of schistosomules by
pLNHX based virions. Human fibrosarcoma HT1080
cells, stably expressing luciferase, and 7 day old
schistosomules were transduced with retroviruses
encoding the shRNA targeting firefly luciferase or a
scrambled sequence (control). As shown in Fig. 2, in
both the HT1080 cells (panel A) and the schistosomes
(panel B), which had been transfected with firefly
luciferase encoding mRNA (mLuc), substantial knockdown of luciferase was apparent in the target HT1080
(47% knockdown) and schistosome parasites (81%)
(Fig. 2, panel A (HT1080 cells), and panel B (schistosomules) when the effect of the pLNHX_HsU6-shLuc
and pLNHX_HsU6_Scram virions was compared.
Similar findings were seen when transduced HT1080
cells were selected on geneticin/G418 for 10 days
(49%) (Figure S1, panel A). Also, similar results were
seen with schistosomules at 10 days after transduction
by virions (60%) and in schistosomules exposed to the
virus by centrifugation (85%) (Figure S1, panels B and
C, respectively).
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Fig. 2 Human U6 gene promoter driving short hairpin RNA
(shRNA) in human HT1080 fibrosarcoma cells and 7 day old
schistosomules of Schistosoma mansoni after transduction with
MLV retroviral virions. a Knockdown of luciferase (47%
knockdown) in HT1080 cells transduced with pLNHX_
HsU6_shLuc (HsU6 shLuc) virions compared to control
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HsU6-shLuc

HsU6-ScramLuc

(HsU6 Scram) virions. b Knockdown (80%) of luciferase in
schistosomules transduced with pLNHX_HsU6_shLuc (HsU6
shLuc) virions compared to control (HsU6 Scram) virions.
Luciferase activity is expressed as relative light units per second
per microgram of soluble protein (RLU/s/lg)
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Human U6 promoter drove stronger shRNA
activity than schistosome U6 promoter
after delivery of transgenes in a transposon
plasmid

Following retroviral transduction, human U6
drives stronger shRNA than schistosome U6
in schistosomules
Having determined above that the heterologous
human U6 promoter was active in shRNA cassettes
in schistosomes, we next compared the performance of
the schistosome and human U6 promoters in schistosomes. Groups of schistosomules were transduced
with pLNHX_HsU6-shLuc, pLNHX_SmU6-shLuc
virions, or control pLNHXDD70 virions. An additional control group, the mock transduction group
exposed only to polybrene, was included. In the
experiment presented in Fig. 3, a knockdown of 38%
luciferase activity was observed in schistosomules
transduced with pLNHX_HsU6-shLuc virions compared to both mock and pLNHXDD70 control groups.
By contrast, no knockdown was observed in worms
transduced with the pLNHX_SmU6-shLuc virions.
This same trend was observed in two replicates of this
experiment (not shown). Thus, the human U6 promoter drove stronger shRNA activity than its schistosome orthologue in S. mansoni. Indeed, the
schistosome promoter was barely or not active under
these conditions.

schistosomules
600

562

500

RLU/s/µg

427

In addition to MLV retroviral based transgenesis of
schistosomes and HT1080 cells to compare the human
and schistosome U6 promoters, we carried out parallel
studies using the piggyBac transposon plasmid pXLBac II (Fig. 1). As above, we targeted HT1080 cells
expressing luciferase and schistosomules transfected
exogenously with luciferase encoding mRNA (mLuc).
First, in each target type, the promoter driving the
shRNA targeting luciferase produced a strong knockdown of luciferase in contrast to the control constructs
targeting the scrambled sequence (Fig. 4, panels A
and B). In both HT1080 and in schistosomules, the
human U6 promoter delivered greater knockdown of
luciferase activity than the schistosome U6 promoter;
88% versus 75% in HT1080, 80% versus 35% in
schistosomules. By contrast, similar levels of luciferase activity were evident in cells (or schistosomes)
transfected with the control constructs, pXL-BacII_
SmU6-shScramLuc (SScram) or pXL-BacII_HsU6shScramLuc (HScram). Similar findings were seen on
each of two occasions these assays were performed
(Figure S2). [Luciferase levels in the mock i.e. no
shRNA control were somewhat higher than in cells (or
schistosomules) transfected with the shRNA control
plasmids, a phenomenon we have seen and discussed
previously (Ayuk et al. 2011)].

436

400
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Discussion

271

200
100
0
SmU6-shLuc

HsU6-shLuc

pLNHX-Δ

mock

Fig. 3 Comparison between human U6 and schistosome U6
promoters driving short hairpin RNA targeting firefly luciferase
in 7 day old schistosomules after transduction with MLV
retroviral virions. Transduction with the human U6 promoter
based pLNHX_HsU6_shLuc virions lead to knockdown (38%)
whereas no knockdown was evident after transduction with the
schistosome U6 promoter based pLNHX_SmU6_shLuc virions,
when compared to the two control groups. These two control
schistosomules were transduced with control MLV (pLNHXD)
virions and not transduced with virions (mock) Luciferase
activity is expressed as relative light units (RLU) per second per
microgram of soluble protein (RLU/s/lg)

Deployment of shRNA for RNA interference represents a new strategy for functional genomics analyses
of schistosomes and the human helminth parasites at
large, which are major neglected disease pathogens.
Whereas this is an emerging area, three recent reports
have shown that both Pol II and Pol III promoters drive
short hairpins in Schistosoma japonicum and
S. mansoni that can silence target genes (Zhao et al.
2008; Tchoubrieva et al. 2010; Ayuk et al. 2011). The
findings revealed that endogenous genes—mago nashi
in S. japonicum and cathepsin B in S. mansoni, as well
as reporter firefly luciferase, can be silenced following
transfection of the schistosomes with transgene cassettes encoding cognate hairpin RNAs. Furthermore,
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Fig. 4 Comparison between human U6 and schistosome U6
promoter driving short hairpin RNAs targeting firefly luciferase
in a HT1080 cell line stably expressing firefly luciferase and in
14 day old schistosomules of Schistosoma mansoni after
transfection with pXL-Bac II plasmids. a Strong knockdown
was seen in cells transfected with both the human U6 (88%
knockdown) and schistosome U6 (75%) promoters in comparison with mock-treatment control. By contrast, less knockdown
was apparent in controls transfected with the human U6 and

schistosome scrambled target sequence based plasmids, 30 and
29% respectively. b In schistosomules, stronger knockdown was
seen with human U6 promoter (80% knockdown) compared
with schistosome U6 promoter (30% knockdown) driving
shRNA after transfection with pXL-Bac II plasmid constructs.
Minimal or no knockdown was seen with the control plasmids,
15 and 0%. In both a and b, luciferase activity is expressed as
relative light units per second per microgram of soluble protein
(RLU/s/lg)

endogenous—S. mansoni actin (Tchoubrieva et al.
2010) and S. mansoni U6 (Ayuk et al. 2011)—and a
heterologous promoter—human H1 (Zhao et al.
2008)—were shown to be active.
Here endo- and exogenous orthologues of U6 gene
promoters were examined for performance in shRNA
expression cassettes in S. mansoni. Promoters from
the genomes of both S. mansoni and Homo sapiens
were tested as components of the shRNA cassettes.
The genomes of both humans and schistosomes
include numerous copies of the U6 small nuclear
RNA gene: there are at least nine copies of the human
U6 gene, five of which are active (Domitrovich and
Kunkel 2003), and nine to 55 copies of the S. mansoni
orthologue (Copeland et al. 2009). The copy of the
human U6 gene promoter tested here appeared to be
identical or close to identical to U6-1 (Domitrovich

and Kunkel 2003), a well-characterized copy that
efficiently drives shRNAs in human cells and cells
from non-congruent species (Boden et al. 2003;
Roelz et al. 2010). We employed both pseudotyped
retrovirus (MLV) and piggyBac based vectors, both
known to integrate transgenes into chromosomes of
this platyhelminth parasite (Morales et al. 2007; Kines
et al. 2008). Notably, the findings revealed that the
human U6 promoter displayed superior performance
to the schistosome U6 orthologue: in both the
retroviral and donor transposon contexts, the human
U6 promoter drove stronger knockdown of firefly
luciferase in a human fibrosarcoma cell line and in
cultured schistosomes.
The promoters were of similar length, 264 nt for
human U6 and 270 nt for S. mansoni, but were only
41% identical. The binding motifs for Pol III in the
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human U6 promoter have been characterized (Domitrovich and Kunkel 2003). They include an enhancer
region, also termed the distal sequence element (DSE).
The DSE consists of an octamer motif (OCT) and a
Sph I post-octamer homology (SPH) element. In
addition, a core region comprises a proximal sequence
element (PSE) and a TATA-like element (Dahlberg
and Schenborn 1988; Sturm et al. 1988; Schaub et al.
1999; Myslinski et al. 2001). Based on greater or lesser
identity to the human and mouse motifs, previously we
identified these prospective motifs of the enhancer and
core regions in the 270 bp upstream of a schistosome
U6 gene (Ayuk et al. 2011). It is feasible that clear
differences in sequence in the PSE and other
domains—for example, TATGATA versus TATATA
for the TATA motif; ATTACTAT versus ATTTGCAT for the OCT motif in the schistosome and human
promoters, respectively (Ayuk et al. 2011)—were
reflected in the differential activity of the human and
schistosome U6 gene promoters. However, confirmation of the influence of these motif differences of the
schistosome and human U6 promoters in schistosomes
awaits further investigation. In addition, other copies
of the S. mansoni U6 promoter may exhibit sequence
differences that drive stronger shRNA expression, as
has been demonstrated among the human U6 gene
orthologues (Domitrovich and Kunkel 2003).
The present results extend earlier findings wherein
it was demonstrated the schistosome U6 promoter
drove shRNA in both targets—HT1080 fibrosarcoma
cells and blood stage schistosomes. However, based
on these findings, we recommend deployment of the
human U6 promoter rather than the schistosome
promoter in future shRNA investigations. Zhao et al.
(2008) demonstrated the activity of the human H1
gene promoter for shRNAs in S. japonicum. Makinen
et al. (2006) demonstrated that the human U6 was
more efficient than the H1 promoter in silencing reporters in both human (293T) and murine
(c166-GFP) cell lines, leading to 80% knockdown of
the transcript encoding green fluorescent protein.
Similar trends were apparent in vivo, in mouse brains.
[H1 RNA is the RNA component of the human nuclear
RNase P; the H1 promoter, which like that of U6 is a
type 3 RNA polymerase III promoter, is unusually
compact (Myslinski et al. 2001).] Moreover, shRNA
expression from the human U6 promoter resulted in a
four-fold increase in knockdown efficiency compared
to expression from the mouse U6 promoter in human
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and in mouse cell lines (Roelz et al. 2010). Accordingly, the human U6 promoter appears in general to
drive strong shRNA based knockdown; the present
findings demonstrated that this also occurs in schistosomes. In less well studied helminth parasites (Rinaldi
et al. 2008), it is reasonable to expect the human U6
gene would also be serviceable for shRNA investigations. Indeed, deploying the human U6 promoter could
provide an initial way forward with functional studies
in less well studied species, for example the helminth
parasites of humanity at large, until endogenous
(congruent) U6 genes could be isolated and tested.
In relation to S. mansoni or other schistosome species,
deploying the human U6 gene promoter should allow
studies to progress while other copies of the schistosome U6 gene can be investigated.
To conclude, these findings indicated superior
performance of a human U6 promoter over a
schistosome U6 promoter in cassettes driving shRNAs
to silence reporter genes in schistosomes, at least in
blood stage schistosomules of S. mansoni. We are
interested to establish long-term, stable and transgenerational RNAi to facilitate investigation of the
essentiality of schistosome genes which could, in turn,
be targeted in new approaches for treatment and
control of schistosomiasis. The human U6 gene
promoter clearly represents a potentially valuable
transgene element for shRNA studies in schistosomes.
High throughput, vector-based RNAi analysis can be
expected to advance functional genomics for schistosomes in assisting the discovery of novel targetable
genes (Stefanic et al. 2010).
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